You are here

STTR Phase I: Nanostraw-mediated Immune Cell Reprogramming

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1549696
Agency Tracking Number: 1549696
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: BT
Solicitation Number: N/A
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-01-01
Award End Date (Contract End Date): 2016-12-31
Small Business Information
655 12th ave
menlo park, CA 94025
United States
DUNS: 078293247
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Ryan Swoboda
 rynswoboda@gmail.com
Business Contact
 Ryan Swoboda
Email: rynswoboda@gmail.com
Research Institution
 Stanford University
 Nicholas A Melosh
 
3160 Porter Drive Suite 100
Palo Alto, CA 94304
United States

 Nonprofit college or university
Abstract

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is a new tool to safely and nondestructively deliver genes and other compounds to individual cells in a laboratory petri dish (in vitro) setting. New forms of therapies for cancer and other intractable diseases take advantage of a patient's own cells, re-engineered in the laboratory to target a tumor or other diseased tissue. However, generating these cells is currently inefficient, slow, and expensive. Patient-derived cells resist transfection using standard non-viral biochemical approaches of lipid delivery systems, cell-penetrating peptides, and high-voltage electroporation, requiring an engineering alternative. A safe, turnkey, and scalable technology would be transformative for research and life sciences companies, and represents a high-growth and high-value market opportunity. This STTR Phase I project proposes a new nanomaterial delivery system to introduce reprogramming agents into immune cells efficiently and with low cell toxicity. This project will examine how the structure and application of the nanomaterial platform dictates the resulting immune cell delivery efficiency, and optimize the process to achieve >50% transfection efficiency with primary immune cells. Achieving this transfection efficiency would be transformative to researchers and clinicians using primary immune cells. The protocol for using these nanomaterials is simple, and turnkey to use for life science researchers. Device costs will be reduced through improved manufacturing techniques to be competitive with currently available methods.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government